| These Explosive Potential Catalysts Could Generate Breakout Buzz For (NYSE American: MAIA)
#1. MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Letter Highlights:
- Phase 2 trial THIO-101 expansion underway; potential filing in 2026 for accelerated approval.
- Phase 3 THIO-104 set to begin in mid-2025; potential filing in 2026 for early full approval.
- Lead asset THIO shows exceptional efficacy in advanced NSCLC.
- Multiple THIO trials planned in additional cancer indications.
- Significant market opportunity in hard-to-treat cancers with unmet medical needs.
#2. Major analyst targets suggest serious upside potential (triple-digit!).
Noble Capital Markets - $14.00 Target - (Potential upside of 450+% from Thursday's close)
Key Report Details:
Conclusion. The design announcement and start of treatment in the final stages of the Phase 2 THIO-101 trial meets our expected timeframe. MAIA has secured supplies of checkpoint inhibitors for its trials and has many clinical milestones in 2025. We reiterate our Outperform rating and $14 price target.
#3. MAIA has a somewhat low float (volatility potential may be explosive).
Sporting a float of roughly 25.05Mn shares, according to Yahoo Finance, volatility potential could pop up in a flash.
#4. MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
"THIO has consistently and substantially outperformed standard treatment options in our THIO-101 Phase 2 trial to date. THIO-104 will give us direct comparative data from a randomized study in patients in third line of treatment," said Vlad Vitoc, M.D., CEO of MAIA. "We expect that the results from this study will further illuminate THIO’s unmatched benefits for advanced stage NSCLC patients."
"Our initiation of THIO-104 will mark an important milestone along our goal for THIO’s FDA commercial approval," Dr. Vitoc added. -----
Coverage is officially reinitiated on MAIA Biotechnology, Inc. (NYSE American: MAIA).
I'll be in touch with updates when necessary. Talk again soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/02/2025 and ending on 05/02/2025 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/maia-kj7gc/#details | 
